Vasilopoulou, E;
Winyard, PJ;
Riley, PR;
Long, DA;
(2015)
The role of thymosin-β4 in kidney disease.
[Editorial comment].
Expert Opinion on Biological Therapy
, 15
, Article Supplement 1. 10.1517/14712598.2015.1009891.
|
Text
Vasilopoulou et al thymosin b4 kidney disease review revision for ucl discovery_template.pdf Download (183kB) | Preview |
Abstract
Therapies that modulate inflammation and fibrosis have the potential to reduce the morbidity and mortality associated with chronic kidney disease (CKD). A promising avenue may be manipulating thymosin-β4, a naturally occurring peptide, which is the major G-actin sequestering protein in mammalian cells and a regulator of inflammation and fibrosis. Thymosin-β4 is already being tested in clinical trials for heart disease and wound healing. This editorial outlines the evidence that thymosin-β4 may also have therapeutic benefit in CKD.
Archive Staff Only
 |
View Item |
